TTX-MC138, an RNA-based therapy from Transcode Therapeutics that’s in early clinical development, induced tumor cell death and prolonged survival in a mouse model of…
News
GYNECOLOGICAL CANCER
Ernexa’s stem cell therapy could soon enter ovarian cancer trials
Ernexa Therapeutics is making headway on plans to start clinical testing of ERNA-101, its stem cell therapy designed to treat ovarian cancer. The U.S.
Medications designed to block a signaling protein called NOTCH3 — which plays a key role in the function and survival of cells in the body…
A Phase 3 clinical trial testing the experimental cancer vaccine galinpepimut-S (GPS) in people with acute myeloid leukemia (AML), a type of blood cancer,…
A new Phase 3 clinical trial has officially begun dosing patients to see if an experimental oral therapy can prevent the recurrence of pancreatic cancer…
VV169, an experimental cellular therapy being developed by Vyriad to treat myeloma, is expected to enter clinical testing in 2026, the…
PANCREATIC CANCER
Pancreatic cancer treatment atebimetinib set for Phase 3 trial
Immuneering is preparing to launch a Phase 3 clinical trial to test its experimental therapy, atebimetinib, in people with…
The first participant has been dosed in an early clinical trial testing the experimental radiation therapy Alpha DaRT in people with hard-to-treat glioma. The…
GYNECOLOGICAL CANCER
New targeted cancer therapy IDE034 heading to Phase 1 clinical trial
A Phase 1 clinical trial testing the experimental therapy IDE034 in people with various types of cancer, including gynecological cancers, is expected to start…
Johnson & Johnson (J&J) is asking the U.S. Food and Drug Administration (FDA) to approve a combination of two medications, Tecvayli (teclistamab) and…
Recent Posts
- New AI-based tool aims to help guide treatment for pancreatic cancer
- Sometimes, in caregiving, acts of love can feel like unkindness
- FDA grants AMXT 1501 orphan drug status for malignant gliomas
- New CAR-NKT cell therapy targets endometrial cancer on two fronts
- Add-on mezigdomide slows cancer progression in hard-to-treat myeloma
